Pfizer's Marketing and Pricing
Of Two Drugs Is Being Probed

Pfizer Inc. disclosed that the marketing and pricing of two of its drugs have drawn increased scrutiny from state and federal prosecutors in recent months.

In a quarterly securities filing, Pfizer said federal investigators have extended a civil probe of the price paid by state Medicaid programs for cholesterol-fighter Lipitor, the company's best-selling drug. Pfizer said the Justice Department is now examining pricing for Lipitor...